340B Drug Discount Program Criticized for Increasing Healthcare Costs
The 340B drug discount program, initially designed to aid hospitals and clinics in low-income areas, is under scrutiny for allegedly being exploited by large health systems. The program mandates pharmaceutical companies to offer drugs at reduced prices to eligible hospitals, which are then reimbursed at standard rates by insurers and government programs. This discrepancy allows hospitals to profit from the difference. Since the Affordable Care Act expanded eligibility, the program's scale has increased significantly, with drug purchases rising from $6.6 billion in 2010 to $66 billion by 2023. Critics argue that this has led to increased use of expensive brand-name drugs, further inflating healthcare costs. 
